Trinity Biotech

Trinity Biotech Asset Growth

The Year-over-Year Total Asset Growth of Trinity Biotech (TRIB) as of Nov 10, 2026 is 1.82 %. In the previous year, Year-over-Year Total Asset Growth was 73.79 % — a change of -97.54% (lower).

Asset Growth

1.82 %

YoY

-97.54%

Last updated:

Year-over-Year Total Asset Growth of Trinity Biotech is 2025 1.82 % . Year-over-Year Total Asset Growth of Trinity Biotech was 2024 73.79 % . It decreases by -97.54% lower compared to the previous year.

The Trinity Biotech Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2018
-21.48 USD
Jan 1, 2019
-13.33 USD
Jan 1, 2020
-0.51 USD
Jan 1, 2021
-8.82 USD
Jan 1, 2022
-22.53 USD
Jan 1, 2023
-35.47 USD
Jan 1, 2024
73.79 USD
Jan 1, 2025
1.82 USD
The Trinity Biotech Asset Growth history
YEARAsset GrowthYoY
1.82 %-97.54%
73.79 %-308.03%
-35.47 %+57.41%
-22.53 %+155.46%
-8.82 %+1,615.35%
-0.51 %-96.14%
-13.33 %-37.94%
-21.48 %-5.89%
-22.83 %-25.07%
-30.47 %-163.72%
47.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Year-over-Year Total Asset Growth of Trinity Biotech is 1.82 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Trinity Biotech

All Key Metrics — Trinity Biotech